{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:50:43Z","timestamp":1790653843482,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Transthyretin (TTR) amyloid cardiomyopathy is a life-threatening condition in which amyloid fibrils accumulate in the heart, eventually leading to cardiac symptomatology and death. To date, treatment of this condition has been directed at symptom relief due to a lack of effective treatment options which target the cause of the disease. The discovery that amyloid deposition was a result of dissociation of the TTR protein structure allowed for the development of tafamidis, which acts by stabilizing the TTR tetramer. Due to the rare nature of the disease, there is limited clinical trial data with tafamidis, with the largest clinical trial enrolling only 441 patients. Nonetheless, that trial demonstrated tafamidis to reduce all-cause mortality as well as cardiovascular hospitalizations compared to placebo with a comparable adverse effect profile, although not all subgroups of patients received benefit. The United States Food and Drug Administration subsequently granted Fast Track review status to tafamidis, leading to its approval in May 2019. Important questions still remain, however, such as which patient groups will receive the most benefit with this drug, how the exceptionally high cost of the drug will be handled by third-party payers, and how the therapeutic role of tafamidis will evolve as competing or perhaps complementary medications complete their ongoing clinical trials and move into the marketplace.<\/jats:p>","DOI":"10.1097\/crd.0000000000000306","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T22:31:09Z","timestamp":1582756269000},"page":"156-160","source":"Crossref","is-referenced-by-count":10,"title":["Tafamidis"],"prefix":"10.1097","volume":"28","author":[{"given":"James J.","family":"Nawarskas","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Shephard","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of New Mexico Hospitals, Albuquerque, NM."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/jsbi.2000.4221","article-title":"Review: history of the amyloid fibril.","volume":"130","author":"Sipe","year":"2000","journal-title":"J Struct Biol"},{"key":"R3-20230903","first-page":"100636","article-title":"New developments in diagnosis, risk assessment and management in systemic amyloidosis.","author":"Vaxman","year":"2019","journal-title":"Blood Rev"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy.","volume":"36","author":"Benson","year":"2007","journal-title":"Muscle Nerve"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis.","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians.","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses.","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement.","volume":"71","author":"Scully","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome.","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd3675","article-title":"Tafamidis.","volume":"11","author":"Said","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","article-title":"The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.","volume":"421","author":"Johnson","year":"2012","journal-title":"J Mol Biol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics.","volume":"299","author":"Hammarstr\u00f6m","year":"2003","journal-title":"Science"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.","volume":"8","author":"Damy","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/j.healun.2019.01.493","article-title":"Efficacy of tafamidis in patients with hereditary or wild-type transthyretin amyloid cardiomyopathy: further results from the ATTR-ACT trial.","volume":"38","author":"Grogan","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R28-20230903","article-title":"Tafamidis \u2014 a pricey therapy for a not-so-rare condition.","author":"Gurwitz","year":"doi:10.1001\/jamacardio.2019.5233","journal-title":"JAMA Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:16:37Z","timestamp":1693732597000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000306"}},"subtitle":["A Novel Treatment for Transthyretin Amyloid Cardiomyopathy"],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000306","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}